FDA source
Kristin Baird FDA medical officer - Baird concluded by reiterating that the primary end point results for Study GVD001/002 were statistically significant and the response measured was durable; moreover, the study data were consistent across subgroups, as well as secondary efficacy end points.
And if you click the link she's got game in the cellular pediatric space
https://www.darkhorseconsultinggroup.com/post/dr-kristin-baird-joins-dark-horse-consulting-as-master-practice-expert
Mesoblast source
Philip Krause- ex FDA - on the record saying efficacy no longer questioned in the CRL
Reg's source
A full bodies Red
FDA sourceKristin Baird FDA medical officer - Baird concluded by...
-
- There are more pages in this discussion • 470 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |